Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 630Prostatic Neoplasms 372Neoplasms 305Carcinoma, Non-Small-Cell Lung 215Lung Neoplasms 204Colorectal Neoplasms 176Multiple Myeloma 143Pancreatic Neoplasms 136Leukemia, Myeloid, Acute 128Neoplasm Metastasis 124Brain Neoplasms 117Melanoma 116Ovarian Neoplasms 101Carcinoma, Hepatocellular 101Precursor Cell Lymphoblastic Leukemia-Lymphoma 100Glioblastoma 99Uterine Cervical Neoplasms 97Head and Neck Neoplasms 94Squamous Cell Carcinoma of Head and Neck 93Colonic Neoplasms 82Stomach Neoplasms 80Recurrence 80Rectal Neoplasms 80Urinary Bladder Neoplasms 77Sarcoma 77Carcinoma, Renal Cell 76Triple Negative Breast Neoplasms 75Lymphoma 71Lymphoma, Non-Hodgkin 67Leukemia, Lymphocytic, Chronic, B-Cell 66

Interventions

zimberelimab 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Urothelial Bladder Carcinoma × Clear all
NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Fundación para el Progreso de la Oncología en Cantabria

Phase 2 Active not recruiting
70 enrolled
Genitourinary

Urothelial Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡